NCT03613246View on ClinicalTrials.gov

NVT ALLEGRA TAVI System TF in Failing Calcified Aortic Heart Valves in a Real-world Patient Population

Active, not recruitingOBSERVATIONAL
Enrollment

346

Participants

Timeline

Start Date

February 20, 2019

Primary Completion Date

December 20, 2024

Study Completion Date

January 26, 2029

Conditions
Transcatheter Aortic Valve Implantation
Trial Locations (14)

20132

Ospedale San Raffaele, Milan

22087

Kath. Marienkrankenhaus, Hamburg

28046

Hospital Universitario La Paz, Madrid

29010

Hospital Universitario Virgen de la Victoria, Málaga

29549

Herz- und Gefäßzentrum Bad Bevensen, Bad Bevensen

30625

MH Hannover, Hanover

36213

Hospital Alvaro Cunqueiro, Vigo

37007

Hospital Universitario de Salamanca, Salamanca

74078

SLK-Kliniken Heilbronn, Heilbronn

90220

Oulu University Hospital, Oulu

Unknown

Schuechtermann-klinik, Bad Rothenfelde

Clinica Mediterranea Neapel, Naples

Morriston Hospital, Swansea

5623 EJ

Heartcentre Catharina Hospital Eindhoven, Eindhoven

All Listed Sponsors
lead

NVT GmbH

INDUSTRY

NCT03613246 - NVT ALLEGRA TAVI System TF in Failing Calcified Aortic Heart Valves in a Real-world Patient Population | Biotech Hunter | Biotech Hunter